ELITech’s COVID, Flu, RSV Multiplex Test Receives CE Mark
December 23, 2020
ELITech Group recently announced its SARS-CoV-2 Plus Elite MGB Kit received CE marking and has been released.
The test kit was developed to distinguish SARS-CoV-2 from other respiratory viruses, including influenza A/B and respiratory syncytial virus types A/B that may have similar symptoms. It runs on the firm’s Elite InGenius platform, as well as other major PCR thermocyclers. The endogenous Internal Control allows confirming the presence and quality of the sample material extracted.
“ELItech is another example of how our BioHive community is responding to COVID-19,” said Kelvyn Cullimore, president and CEO of BioUtah. “We’re proud of how EliTech and Utah’s life sciences companies are working to help keep us safe and healthy.”
Roberto Meda, Vice President MDx, ELITechGroup is excited to offer such an important multiplex Sample-to-Result solution for the detection of the SARS-CoV-2, Flu A, Flu B, and RSV viruses. This achievement was made possible by the dedication and collaboration of all EG teams involved.
Recent News
- BD Launches Landmark Cell Analyzer Featuring Breakthrough Spectral and Real-Time Cell Imaging Technologies
- KyphoLift Debuts at ISMRM 2025: Transforming Patient Positioning for Safer, More Accurate Imaging
- Kelvyn Cullimore: An Unfair Penalty on Life-Saving Pills
- Merit Medical Announces Health Canada Approval of the WRAPSODY® Cell-Impermeable Endoprosthesis
- Merit Medical Releases 12-Month Efficacy Results for the Single-Arm Arteriovenous Graft (AVG) Cohort of the WRAPSODY® Arteriovenous Efficacy (WAVE) Trial
- Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology